New hope for rare skin Flare-Ups: drug offered to those with no options
NCT ID NCT05239039
First seen Nov 01, 2025
Summary
This program in China gave a single infusion of spesolimab to 39 people with a severe skin condition called generalized pustular psoriasis (GPP) during a flare-up. Participants had no other treatment options available. The goal was to control the flare and monitor for side effects over about 4 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Friendship Hospital
Beijing, 100050, China
-
Dermatology Hospital, Chinese Academy of Medical Sciences
Nanjing, 210000, China
-
Hangzhou Third People's Hospital
Hangzhou, 310013, China
-
Shandong Provincial Hospital of Dermatology
Jinan, 250063, China
-
Shanghai Skin Disease Hospital
Shanghai, 200000, China
-
Southern Medical University Dermatology Hospital
Guangzhou, 510091, China
-
The First Hospital of China Medical University
Shenyang, 110001, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, 310009, China
-
The University of Hong Kong-Shenzhen Hospital
Shenzhen, 518053, China
-
Tianjin Medical University General Hospital
Tianjin, 30052, China
-
West China Hospital
Chengdu, 610041, China
-
Wuhan Union Hospital
Wuhan, 430022, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.